Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering...
Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering some of its earlier 6% dip on some upbeat preliminary FY12 guidance posted over the weekend. The company said that it is expecting revenues of $89M, equating to a Y/Y growth rate of 59%, but the results were largely overshadowed by Illumina's (ILMN -7.3%) acquisition of Verinata, whose competing verifi test - which analyzes fetal DNA naturally found in a pregnant women's blood to look for missing or extra copies of chromosomes - carry's less risk than Sequenom’s SEQureDx technology.
Check out Seeking Alpha’s new Earnings Center »
From other sites
at Benzinga.com (Feb 26, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs